AU2020263709A1 - Method of treatment - Google Patents

Method of treatment Download PDF

Info

Publication number
AU2020263709A1
AU2020263709A1 AU2020263709A AU2020263709A AU2020263709A1 AU 2020263709 A1 AU2020263709 A1 AU 2020263709A1 AU 2020263709 A AU2020263709 A AU 2020263709A AU 2020263709 A AU2020263709 A AU 2020263709A AU 2020263709 A1 AU2020263709 A1 AU 2020263709A1
Authority
AU
Australia
Prior art keywords
agent
seq
protein
nomacopan
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020263709A
Other languages
English (en)
Inventor
Virginia CALDER
Wynne H. Weston-Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Publication of AU2020263709A1 publication Critical patent/AU2020263709A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020263709A 2019-04-25 2020-03-04 Method of treatment Abandoned AU2020263709A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1905810.6 2019-04-25
GBGB1905810.6A GB201905810D0 (en) 2019-04-25 2019-04-25 Method of treatment
GB2000955.1 2020-01-22
GBGB2000955.1A GB202000955D0 (en) 2019-04-25 2020-01-22 Method of treatment
PCT/EP2020/055741 WO2020216513A1 (en) 2019-04-25 2020-03-04 Method of treatment

Publications (1)

Publication Number Publication Date
AU2020263709A1 true AU2020263709A1 (en) 2021-12-23

Family

ID=66810336

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020263709A Abandoned AU2020263709A1 (en) 2019-04-25 2020-03-04 Method of treatment

Country Status (10)

Country Link
US (1) US20220211810A1 (https=)
EP (1) EP3958974A1 (https=)
JP (1) JP7603612B2 (https=)
KR (1) KR20220018963A (https=)
CN (1) CN114072206B (https=)
AU (1) AU2020263709A1 (https=)
CA (1) CA3137240A1 (https=)
GB (2) GB201905810D0 (https=)
IL (1) IL287250A (https=)
WO (1) WO2020216513A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
WO2024238859A1 (en) * 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized c5 inhibitor agents and administration thereof
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1629098B1 (en) 2003-06-02 2009-04-01 Varleigh Limited Complement inhibitors from ticks
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
PL2061501T3 (pl) 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
AU2008228247A1 (en) * 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
SI2173890T1 (sl) * 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
JP5840623B2 (ja) 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
GB201401453D0 (en) * 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CA2988313A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
EP3359566A1 (en) * 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
SG11201811491YA (en) * 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
AU2018226872A1 (en) * 2017-03-03 2019-09-05 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
WO2018193120A1 (en) * 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of cicatrising eye inflammatory disorders
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
US11730792B2 (en) * 2017-04-21 2023-08-22 Volution Immuno Pharmaceuticals Sa Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA)
JP7629394B2 (ja) * 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
US20220370556A1 (en) * 2019-09-27 2022-11-24 Volution Immuno Pharmaceuticals Sa Method of Treatment

Also Published As

Publication number Publication date
JP2022530068A (ja) 2022-06-27
GB202000955D0 (en) 2020-03-04
EP3958974A1 (en) 2022-03-02
US20220211810A1 (en) 2022-07-07
CN114072206A (zh) 2022-02-18
CA3137240A1 (en) 2020-10-29
JP7603612B2 (ja) 2024-12-20
GB201905810D0 (en) 2019-06-05
WO2020216513A1 (en) 2020-10-29
IL287250A (en) 2021-12-01
CN114072206B (zh) 2024-11-08
KR20220018963A (ko) 2022-02-15

Similar Documents

Publication Publication Date Title
CN110896606B (zh) 用于治疗自身免疫性水疱病的coversin
US20220211810A1 (en) Method of Treatment
CA2666843C (en) Treatment of age-related macular degeneration and other diseases of the eye
JP2024167222A (ja) 加齢黄斑変性の治療における融合タンパク質の使用
JP7068706B2 (ja) 網膜神経変性疾患の眼局所治療のためのジペプチジルペプチダーゼ－４阻害剤
AU2019468121A1 (en) Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
US20200138903A1 (en) Socs1-derived peptide for use in chronic complications of diabetes
CN112469430B (zh) 抑制大脑炎症的方法
WO2013005603A1 (ja) 結膜におけるアレルギー性炎症の予防及び／又は治療剤
US10232019B2 (en) Method of treating hyperglycemic disorders using apolipoprotein AIV
TW201109029A (en) Vaccine therapy for choroidal neovascularization
WO2024115767A1 (en) Nomacopan-pas fusion proteins
AU2012314330B2 (en) Compositions and methods for the treatment of degenerative retinal conditions
WO2018088464A1 (ja) 脳梗塞の治療薬
Dabouz Neuro-immune interactions in age-related macular degeneration: implications for future therapeutics

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted